Drug developer Seaport Therapeutics targets $912 million valuation in US IPO

Chronological Source Flow
Back

AI Fusion Summary

Seaport Therapeutics aims for a $912 million valuation in its upcoming U.S. initial public offering. Meanwhile, HawkEye, a space analytics company, seeks a $2.4 billion valuation in its U.S. IPO.
#SEAPORT_THERAPEUTICS #HAWKEYE #US_IPO #SPACE_ANALYTICS #DRUG_DEVELOPER #VALUATION
27/04 13:54 investing.com
4 Πηγές

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO

POLITICS
27/04 14:21 yahoo.com

Space analytics firm HawkEye targets $2.4 billion valuation in US IPO

27/04 14:25 investing.com

Space analytics firm HawkEye targets $2.4 billion valuation in US IPO

27/04 14:32 investing.com

HawkEye 360 targets up to $2.42 billion valuation in US IPO

Comments
Loading...
0